JP Morgan Chase
XLO icon

JP Morgan Chase’s Xilio Therapeutics XLO Stock Holding History

JP Morgan Chase’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98K Buy
+240
New +$1.97K ﹤0.01% 7017
2025
Q2 		– Sell
-4
Closed -$45 – 7715
2025
Q1 		$45 Sell
4
-1
-20% -$13 ﹤0.01% 7000
2024
Q4 		$63 Hold
5
– – ﹤0.01% 7088
2024
Q3 		$59 Buy
5
+1
+25% +$12 ﹤0.01% 7087
2024
Q2 		$56 Sell
4
-192
-98% -$3.01K ﹤0.01% 7010
2024
Q1 		$2.96K Sell
196
-8
-4% -$77 ﹤0.01% 6529
2023
Q4 		$1.57K Buy
204
+10
+5% +$198 ﹤0.01% 6759
2023
Q3 		$5.74K Buy
194
+1
+0.5% +$37 ﹤0.01% 6356
2023
Q2 		$7.08K Hold
193
– – ﹤0.01% 6108
2023
Q1 		$9K Hold
193
– – ﹤0.01% 6144
2022
Q4 		$7K Hold
193
– – ﹤0.01% 6106
2022
Q3 		$8K Sell
193
-2
-1% -$78 ﹤0.01% 6011
2022
Q2 		$8K Sell
195
-151
-44% -$7.99K ﹤0.01% 6083
2022
Q1 		$34K Sell
346
-489
-59% -$77.4K ﹤0.01% 5928
2021
Q4 		$187K Buy
+835
New +$199K ﹤0.01% 5401

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's XLO Position: Q1 2026 in Review

JP Morgan Chase opened a new position in Xilio Therapeutics (XLO) in Q1 2026: 240 shares worth $1.98K. The stake represents ﹤0.01% of the portfolio and ranks #7017 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in XLO as recently as Q1 2025.

JP Morgan Chase first reported a position in XLO in Q4 2021 and has held it in 15 quarters since. The position peaked at $187K in Q4 2021. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • JP Morgan Chase held 240 shares of Xilio Therapeutics worth $1.98K as of Q1 2026.
  • Xilio Therapeutics was a new JP Morgan Chase position in Q1 2026.
  • Xilio Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7017 holding.
  • JP Morgan Chase first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • JP Morgan Chase's Xilio Therapeutics position peaked at $187K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.